Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013

J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-9. doi: 10.6004/jnccn.2012.0128.

Abstract

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma. These include the addition of regimens containing novel agents as primary and salvage therapy options, inclusion of the updated summary of response categories and criteria from the sixth international workshop on Waldenström's Macroglobulinemia, and a section on management of peripheral neuropathy in the accompanying discussion.

Publication types

  • Practice Guideline

MeSH terms

  • Algorithms
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antineoplastic Agents / adverse effects
  • Drug-Related Side Effects and Adverse Reactions / therapy
  • Humans
  • Immunoglobulin M / immunology
  • Medical Oncology / trends*
  • Neoadjuvant Therapy
  • Peripheral Nervous System Diseases / immunology
  • Peripheral Nervous System Diseases / therapy
  • Practice Guidelines as Topic
  • Prognosis
  • Recurrence
  • Rituximab
  • Salvage Therapy
  • Waldenstrom Macroglobulinemia / diagnosis
  • Waldenstrom Macroglobulinemia / therapy*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Immunoglobulin M
  • Rituximab